ASAM Pocket Guidelines and Patient Guide

Stimulant Use Disorder

ASAM Opioid Addiction Treatment GUIDELINES Apps and Pocket Guides brought to you courtesy of Guideline Central. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1519511

Contents of this Issue

Navigation

Page 22 of 29

23 Indications Other considerations Excitatory symptoms Anxiety/Agitation Neuromuscular excitation Seizures Parenteral vs. PO administration based on signs and symptom severity and drug availability (eg, parenteral BZD shortages). IM administration allows for administration in agitated patients without IV access. Lorazepam has very slow IM onset (15–30 min) Midazolam has very rapid IV onset, allowing for easy titration, and a relatively fast IM onset If psychosis is primary symptom, antipsychotics should be considered primarily or adjunctively BZD shortages or contraindications Patient not responding to escalating doses of BZDs Severe sympathomimetic intoxication High oral bioavailability; PO dosing can be similar to parenteral dosing Onset of effects, while slower than IV, is still fairly quick compared to other PO medications For critically ill patients in the intensive care unit (ICU) Severe sympathomimetic intoxication not responding to other agents Patients can be administered BZDs, PBO, and/or propofol concomitantly Intubation is almost always required for propofol administration Anxiety Useful medication adjunct to BZDs Maintain hydration to avoid orthostatic symptoms For critically ill patients in the ED or ICU as primary or secondary medication for sedation Useful medication adjunct to BZDs or other sedation agents Onset of effects generally 30–60 min Sedation without impairments in ventilation

Articles in this issue

view archives of ASAM Pocket Guidelines and Patient Guide - Stimulant Use Disorder